Picture of Milestone Pharmaceuticals logo

MIST — Milestone Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview

* Milestone Pharmaceuticals Inc  MIST.OQ   MIST.O  is
expected
to show no change in quarterly revenue when it reports 
results on August 8 (estimated) for the period ending June
30 2024
    * 
    * ​LSEG's mean analyst estimate for Milestone
Pharmaceuticals Inc
is for a loss of 19 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Milestone
Pharmaceuticals Inc is $7.00​, above​ its last closing price
of $1.29. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.25       -0.26      -0.21     Beat    19.2
 Dec. 31 2024  -0.30       -0.31      -0.32     Missed  -2.4
 Sep. 30 2023  -0.38       -0.38      -0.35     Beat    8.4​
 Jun. 30 2023  -0.38       -0.39      -0.37     Beat    4.1
 ​​Mar.        -0.40       -0.40      -0.35     Beat    12.1
 31 2023                                                
 Dec. 31 2022              -0.33      -0.31     Beat    7.5​
 Sep. 30 2022  -0.40       -0.41      -0.34     Beat    16.7
 Jun. 30 2022  -0.34       -0.36      -0.39     Missed  -8.3
 This summary was machine generated August 6 at 16:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Milestone Pharmaceuticals

See all news